Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events

Unprecedented successes regarding cancer immunotherapy have been achieved, in which therapeutic agents are used to target immune cells rather than cancer cells. The most effective immunotherapy to date is the group of immune checkpoint inhibitors (CPI), targeting, for example, cytotoxic T-lymphocyte...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:ESMO Open
Egile Nagusiak: Hoefsmit, Esmée P., Rozeman, Elisa A., Haanen, John B. A. G., Blank, Christian U.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2019
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6677983/
https://ncbi.nlm.nih.gov/pubmed/31423333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000472
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak